Agenus announces new responses for agen1181

Lexington, mass., feb. 09, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its phase 1/2 trial of agen1181, its next-generation anti-ctla-4, as monotherapy and in combination with agenus' anti-pd-1 balstilimab.
AGEN Ratings Summary
AGEN Quant Ranking